Breast cancer detection using automated whole breast ultrasound and mammography in radiographically dense breasts

Abstract Purpose: Mammography, the standard method of breast cancer screening, misses many cancers, especially in dense-breasted women. We compared the performance and diagnostic yield of mammography alone versus an automated whole breast ultrasound (AWBU) plus mammography in women with dense breasts and/or at elevated risk of breast cancer.

Methods: AWBU screening was tested in 4,419 women having routine mammography (Trial Registration: ClinicalTrials.gov Identifier: NCT00649337). Cancers occurring during the study and subsequent 1-year follow-up were evaluated. Sensitivity, specificity and positive predictive value (PPV) of biopsy recommendation for mammography alone, AWBU and mammography with AWBU were calculated.

Results: Breast cancer detection doubled from 23 to 46 in 6,425 studies using AWBU with mammography, resulting in an increase in diagnostic yield from 3.6 per 1,000 with mammography alone to 7.2 per 1,000 by adding AWBU. PPV for biopsy based on mammography findings was 39.0% and for AWBU 38.4%. The number of detected invasive cancers 10 mm or less in size tripled from 7 to 21 when AWBU findings were added to mammography. Conclusion: AWBU resulted in significant cancer detection improvement compared with mammography alone. Additional detection and the smaller size of invasive cancers may justify this technology’s expense for women with dense breasts and/or at high risk for breast cancer.

Keywords Mammography · Ultrasound · Breast cancer · Screening · Automated

Introduction

Despite progress in identifying risk factors and genetic markers for breast cancer, approximately 70–80% of cases occur in women without known major predictors [1–3]. Population-based screening for early detection of breast cancer is therefore the primary strategy for reducing breast cancer mortality.

Mammography as the standard imaging method for breast cancer screening [4] has resulted in reduced breast cancer mortality. However, the number of cancers escaping detection with mammography is substantial, particularly in dense-breasted women, with sensitivity as low as 30–48% [5]. Computer-aided detection (CAD) improves sensitivity but does not identify all cancers [6, 7]. The DMIST trial found an improvement from 55% to 70% in cancer detection comparing digital with film mammography [8], suggesting that substantial numbers of cancers are missed even with digital technology. Mammographically missed cancer is a particular problem for women with dense breasts [5, 9]; Boyd et al. showed that the odds for interval cancers was 17.8-fold higher in extremely dense breasts compared with fatty breasts [9].

The performance of mammography is reduced for cancer detection in dense-breasted women as mammograms are summation images, with all breast tissue overlapping in
each view. Cancers may not be visualized because of overlying dense breast tissue [10–11]. Mammography can miss far posterior cancers in the retro-mammary space because of inadequate positioning of deep tissue [10]. Magnetic resonance imaging (MRI) has recently been recommended by the American Cancer Society (ACS) to screen women at very high risk of breast cancer [12]. Though highly sensitive, MRI is costly and may carry risks from the required contrast media [13]. MRI for breast cancer screening has also been characterized by lower specificity, as compared to mammography with a higher rate of false positives, leading to further follow-up MRI and/or image-guided biopsy costs [14–17]. For example, a study by Leach et al. reported MRI specificity of 81%, compared to 93% specificity in mammography [18]. Griebisch et al. [14] reported MRI as having almost four times more recalls than mammography for women with high familial breast cancer risk, and 70% of the recalls did not involve cancer. Because of lower specificity and higher cost, compared to mammography, MRI may not be optimal for breast cancer screening.

Ultrasound is an attractive supplement to mammography because it is widely available, relatively inexpensive and well-tolerated by patients [19–21]. Ultrasound images the tissue to the chest wall in all but the very largest patients, and is a cross-sectional technique, displaying tissue without overlap. Early reports using high-resolution ultrasound for breast cancer detection have been promising [22–29], but the time and skill necessary to detect small, non-palpable tumors with hand-held imaging has discouraged widespread use [30, 31]. Berg et al. (ACRIN study) [32] noted that lack of uniformity and shortage of qualified personnel limit wide implementation of hand-held imaging.

The automated whole-breast ultrasound (AWBU: Sonocine, Inc., 5475 Reno Corporate Dr., Suite 200, Reno, NV 89511) system gathers standardized uniform image sets by lesser trained personnel, allowing shorter, more efficient time use by physicians interpreting the studies. Previous studies have shown that 3D AWBU is feasible [33, 34]. Previous studies have also shown that 3D AWBU has excellent interobserver variability with 2D benign and malignant lesions [35]. The aim of this study was to determine the improvement in diagnostic yield in detecting non-palpable breast cancer in asymptomatic women with 2D AWBU added to mammography.

**Materials and methods**

**Participants**

From January 2003 to July 2007, women were recruited for AWBU studies at presentation for routine mammography at eight facilities in Pasadena, Redding, Santa Barbara, Orange and Solano Beach, CA; Albuquerque, NM; Atlanta, GA; and Ogden, UT. Study participation was offered to consecutive asymptomatic women who had BI-RADS density 3 or 4, heterogeneously or extremely radiographically dense breasts, family or personal history of breast cancer, and/or implants, and who were at least 35 years old unless they had a family or personal history of breast cancer. Women with greater than 7 cm compressed breast thickness at mammography were specifically not recruited because of ultrasound’s limited effectiveness in identifying small masses at these depths, and the resultant decreased reliability of AWBU for these women. Asymptomatic participants were individually interviewed, given a detailed verbal explanation of the study protocol and consent, and interviewed to confirm they were asymptomatic. The percentage of women volunteering for AWBU varied by site. Approximately 5% of those eligible volunteered at sites that only informed the women of the study by mail and required them to make AWBU appointments at the same time as their mammograms. Up to 25% of women volunteered when informed of the study by personnel at the breast center and offered immediate AWBU in conjunction with their mammograms.

The study consent was approved by the Institutional Review Boards at each hospital, or The Western Institutional Review Board. The consent specifically stated that AWBU is an investigational procedure meant to supplement, not replace, mammography.

A total of 6,425 AWBU examinations and mammograms were performed on 4,419 asymptomatic women; 4,991 of the mammograms were routine screening studies, and 1,434 were annual asymptomatic diagnostic, immediate review studies (22%), including 776 with previous breast cancer, 399 with implants and 159 with non-localized findings such as diffuse nodularity or diffuse breast tenderness. A third (36%; n=2297) of the mammograms were digital, and two thirds analog. Participants had the option of having AWBU concurrent with mammography (3,951 women) or alternating mammography and AWBU every 6 months (468 women) according to the preference of the individual woman. Some women who had had previous breast cancer or who had a strong family history of breast cancer preferred to be examined by mammography or AWBU at approximately 6-month intervals. Matching studies were included in the analyses if the examinations fell within a reasonable window, defined as 34 days for participants opting for concurrent screenings and 5–8 months for patients alternating techniques. Participants were included in the analysis if they were asymptomatic and had at least one pair of matching examinations within the allowed times. Six paired examinations were incomplete or probably benign (BI-RADS 0 or 3), but the patients had not completed follow-up and were excluded from the analysis. Fifty patients were excluded for the following reasons: 35 had palpable findings, including 5 palpable cancers; 15 elected AWBU after an abnormal mammogram, including 5 cancers, and
were excluded because the AWBU interpretation was not blinded to mammography findings. Eleven biopsies were excluded for the following reasons: six patients had biopsies over a year after AWBU, including 2 cancers; four had benign biopsies performed for findings seen with MRI only; one participant had therapeutic seroma drainage.

One of ten radiologists, FDA-qualified in mammography and with at least 10 years’ experience in breast ultrasound, interpreted each AWBU study. The mammograms were interpreted by a single radiologist in the usual manner for that institution. The radiologists were blinded to the results of the corresponding mammograms or AWBU studies, and in some cases the same radiologist interpreted both studies.

The mammograms of all participants with cancers detected by AWBU were retrospectively reviewed, ensuring that the original reader had not missed a mammographically detectable cancer. Mammograms and AWBU studies of all participants with clinically detected interval cancers occurring within 1 year of a normal mammogram were similarly reviewed. Mammographic follow-up for at least 1 year since the index imaging was available for 5,089 examinations (80.0%).

Diagnostic tool

AWBU is a computer-based system for performing and recording ultrasound of the whole breast (SonoCine, Reno, NV). The images were collected with multi-frequency transducers within at least the 7 to 12 mHz range. The ultrasound systems used are the Phillips iU22, the Siemens Sequoia, the GE Logiq 9 and the ATL HDI 5000. The transducer is attached to a computer-guided mechanical arm, and images acquired in longitudinal rows (acquiring transverse images), overlapping 7 to 10 mm to ensure complete coverage. As the transducer faces in more than 95% of the examinations measured 5.2 cm, the width of the rows without the overlap was about 4.2 to 4.5 cm. In most women the number of rows varied from 4 to 7 for each breast. The mechanical arm controls transducer speed and position, with a trained ultrasound technologist maintaining appropriate contact pressure and orientation vertical to the skin. Approximately 150–300 images per row are immediately displayed on the AWBU monitor and then permanently stored. The interval between recorded images is 0.8 mm. Typical imaging time is 10–20 min for each participant, with additional participant preparation times of 5–10 min. Interpretation and reporting time for an experienced radiologist was 7–10 min per examination for typical AWBU studies.

AWBU software creates a cine loop of the images for interpretation, simulating the appearance of real-time imaging. Each cine loop varies from 2,000 to 5,000 images depending on breast size, with about 3,000 images for the average woman. Lesion detection is enhanced by review of the cine loop at about 10 images per second to simulate motion through the breast. Single still images are reviewed only after a possible abnormality has been identified. Any point on an image can be identified as a distance from the nipple in a specific radius using spatial registration recorded as images are acquired. Image review is optimized by playback on a high-resolution monitor allowing compressed image size, three-dimensional reconstruction, and adjustment of contrast, brightness and review speed.

Studies were reported according to the American College of Radiology Breast Imaging Reporting and Data System (BI-RADS) six-point scale (0= incomplete, needs additional assessment; 1= normal; 2= benign; 3= probably benign; 4= suspicious; 5= highly suggestive of malignancy) [36, 37].

Follow-up

Data were collected for size, stage and grade of cancers detected by imaging and during a 1-year follow-up period. When both studies were normal, no further action was required. If the results of AWBU, mammography or both required further action, additional evaluation was completed unless the initial abnormal finding was fully explained by the other imaging study. For examinations scored as 0 or 3, additional imaging was performed to determine the final BI-RADS assessment.

If the BI-RADS score was 4 or 5, a stereotactic radiographic or ultrasound directed 14 gauge or larger percutaneous biopsy was performed. If a benign non-high-risk lesion was diagnosed, no further tissue sampling was performed. If a focal high-risk lesion, such as atypical ductal hyperplasia, papillary neoplasm or radial scar, was discovered, the diagnosis was confirmed by surgical removal of the lesion. If a malignancy was found, the lesion was removed surgically by lumpectomy or mastectomy, and a final pathological stage was assigned by the pathologists in the usual manner for that hospital in accordance with the American Joint Committee on Cancer (AJCC) TNM system guidelines. The pathologists were blinded to the patients’ participation in the study and the method of cancer detection.

Statistical analysis

Improvements in diagnostic yield were assessed by calculation of the sensitivity, specificity and positive predictive value (PPV) for biopsy recommendation based on mammography plus AWBU, compared with mammography. Analyses were carried out using SAS version 9.1 software [38]. Exact 95% confidence intervals (CI) were calculated for diagnostic yield [39]. Chi-square test
A statistic was used to compare the number of cancers detected by AWBU, based on the size of cancer. McNemar’s test was conducted to compare diagnostic yield between mammography and AWBU. We compared the PPV between mammography and AWBU following methodology proposed by Leisenring [40]. P-values of less than 0.05 were considered to indicate statistical significance.

Results

Participants

Ethnic groups in the study (n=4419) were whites (87%; n=3843), Hispanics (6%; n=248), Asians (3%; n=128) and blacks (1%; n=61). More than half of the participants reported never taking hormone replacement therapy (59%; n=2,618); 11% (n=500) of all participants and 5% (3 out of 57) of participants found to have breast cancer had implants. Personal history of breast cancer was reported in 10% of participants (n=432) and first or second degree relatives with breast cancer in 30% (n=1,314) and 29% (n=1,280), respectively. Four participants (0.1%) have a known mutation of BRCA1/2. None of the above-mentioned breast cancer risk factors were reported by 1,279 (29%). Median age of the study population was 53 years (range=24 to 89).

Breast cancer detection

There were 57 cancers in 56 participants (1.3% of the sample); one participant had bilateral cancer. Mean age of participants with breast cancer (n=56) at the time of biopsy was 57 years; 14 cancers occurred in women younger than 50, and 8 patients were at least 70. Cancer detection was added for patients in all age groups, but age subsets were too small for statistical analysis. Three quarters (43 out of 57) of breast cancers were reported to have breast cancer had

Table 1 Non-palpable breast cancer detection by imaging method

<table>
<thead>
<tr>
<th>Cancer types</th>
<th>Number of cancers</th>
<th>Imaged only by AWBU</th>
<th>Imaged by both AWBU and mammography</th>
<th>Imaged by mammography only</th>
<th>Neither a</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>n (%)</td>
<td>95% CI b</td>
<td>n (%)</td>
<td>n (%)</td>
</tr>
<tr>
<td>All cancers</td>
<td>57</td>
<td>23 (40)</td>
<td>(27.5,54)</td>
<td>15 (26)</td>
<td>8 (14)</td>
</tr>
<tr>
<td>Stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>7</td>
<td>1 (14)</td>
<td>(0,58)</td>
<td>2</td>
<td>4 (14)</td>
</tr>
<tr>
<td>1</td>
<td>33</td>
<td>17 (51.5)</td>
<td>(33.5,69)</td>
<td>10</td>
<td>3 (9)</td>
</tr>
<tr>
<td>2a</td>
<td>10</td>
<td>4 (40)</td>
<td>(12.7,49)</td>
<td>2</td>
<td>0 (0)</td>
</tr>
<tr>
<td>2b</td>
<td>3</td>
<td>0 (0)</td>
<td>(0.71)</td>
<td>1</td>
<td>1 (3)</td>
</tr>
<tr>
<td>3a</td>
<td>2</td>
<td>1 (50)</td>
<td>(1.99)</td>
<td>0</td>
<td>1 (3)</td>
</tr>
<tr>
<td>3b</td>
<td>2</td>
<td>0 (0)</td>
<td>(0.84)</td>
<td>0</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Ductal carcinoma in situ</td>
<td>7</td>
<td>1 (14)</td>
<td>(0.58)</td>
<td>2 (28.5)</td>
<td>4 (57)</td>
</tr>
<tr>
<td>Invasive cancer</td>
<td>50</td>
<td>22 (44)</td>
<td>(30.5,59)</td>
<td>13 (26)</td>
<td>4 (8)</td>
</tr>
<tr>
<td>Invasive ductal</td>
<td>42</td>
<td>18 (43)</td>
<td>(28.5,59)</td>
<td>12 (28.5)</td>
<td>3 (7)</td>
</tr>
<tr>
<td>Invasive lobular</td>
<td>8</td>
<td>4 (50)</td>
<td>(16.84)</td>
<td>1 (12.5)</td>
<td>1 (12.5)</td>
</tr>
<tr>
<td>Grade of invasive cancers c</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>15</td>
<td>7 (47)</td>
<td>(21.73)</td>
<td>5 (33)</td>
<td>1 (7)</td>
</tr>
<tr>
<td>II</td>
<td>21</td>
<td>13 (62)</td>
<td>(38.82)</td>
<td>5 (24)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>III</td>
<td>13</td>
<td>2 (15)</td>
<td>(2.45)</td>
<td>2 (15)</td>
<td>3 (23)</td>
</tr>
<tr>
<td>Size of invasive cancers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 mm or less c</td>
<td>3</td>
<td>1 (33)</td>
<td>(1.90.5)</td>
<td>1 (33)</td>
<td>1 (33)</td>
</tr>
<tr>
<td>6 to 10 mm</td>
<td>18</td>
<td>13 (72)</td>
<td>(46.5,90)</td>
<td>3 (17)</td>
<td>2 (11)</td>
</tr>
<tr>
<td>11 to 20 mm</td>
<td>20</td>
<td>6 (30)</td>
<td>(12.54)</td>
<td>8 (40)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>21 to 50 mm</td>
<td>6</td>
<td>1 (17)</td>
<td>(0.64)</td>
<td>1 (17)</td>
<td>1 (17)</td>
</tr>
<tr>
<td>over 5 cm</td>
<td>3</td>
<td>1 (33)</td>
<td>(1.90.5)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
</tbody>
</table>

Abbreviations: AWBU, automated whole breast ultrasound; CI, confidence intervals.

aInterval cancers detected within a year of negative imaging.
b95% confidence intervals for additional cancers detected only by AWBU.
cOne tumor was detected as a lymph node metastasis, with no primary tumor identified by mammography, ultrasound or MRI.
familial or familial risk factors; 11 cancers were reported in participants with a personal history and first- or second-degree relatives with breast cancer, 8 cancers were reported in participants with only a personal history, and 24 were reported in participants only reporting relatives with breast cancer. No participants with cancer had a known BRCA mutation. Only three cancers were observed in participants alternating AWBU/mammography screenings every 6 months.

Breast cancer detections doubled from 23 to 46 in 6,425 studies using AWBU with mammography, resulting in an increase in diagnostic yield from 3.6 per 1,000 with mammography alone to 7.2 per 1,000 by adding AWBU (an additional 3.6 per 1,000; 95% CI=2.3–5.4). Sensitivity for mammography alone was 40% (95% CI=27.5–54%; 23 out of 57 cancers), but increased to 81% (95% CI=68–90%; 46 out of 57 cancers) with the addition of AWBU. Sensitivity of AWBU alone was 67% (95% CI=53–79%; 38 out of 57).

Table 1 shows significant increases in invasive ductal cancer detections; 18 out of 42 invasive ductal cancers were demonstrated by AWBU only (95% CI=28–59%), among grade I invasive cancers (95% CI=21–73%) and grade II invasive cancers (95% CI=38–82%). Additional grade III invasive cancer detections were 15% (95% CI=2–45%). Significantly smaller invasive tumors were detected by AWBU; 14 out of 21 (p=0.006), or 67% of cancers less than 10 mm or less were detected only by AWBU and not evident by mammography. The sensitivity of AWBU for these tumors was 81% compared with 33% for mammography. Cancer detections for invasive tumors measuring 11 to 20 mm increased from 8 to 14 with the addition of AWBU. Selected AWBU and mammography images of a woman with dense breasts are shown in Fig. 1, demonstrating bilateral cancers evident with AWBU but not mammography.

For women with dense or extremely dense breasts (Table 2), AWBU detected 32 out of 49 cancers or 65%, compared with 19 out of 49, or 39% for mammography alone (p=0.02). Addition of AWBU to mammography more than doubled cancer detections from 19 to 39.

AWBU resulted in more recalls for additional imaging (Table 3) than mammography (p < 0.001). Recalls were 4.2% for screening mammography and 7.2% for AWBU. Recalls increased from 4.2 to 9.6% adding AWBU to mammography, as some AWBU-recalled participants were the same participants recalled because of mammography findings. The 208 screening mammography recalls resulted in 13 cancer diagnoses (yield 6.25%); 465 AWBU recalls resulted in 38 cancer diagnoses (yield 8.2%).

Specificity based on recalls was 89.9% (95% CI=89.1–90.6%) for AWBU, 95.15% (95% CI=94.6–95.7%) for mammography and 98.7% (95% CI=98.35–98.9%) for combined mammography/AWBU. Table 4 outlines the likelihood of cancer per biopsy recommendation, i.e., PPV of cancer. No difference in the probability of cancer was found according to the type of diagnostic test leading to biopsy.

Fig. 1 Selected images of a 54-year-old asymptomatic woman with dense breasts and no previous history of breast cancer. a Craniocaudal digital mammograms taken the same day as the AWBU study. b Mediolateral oblique digital mammograms taken the same day as the AWBU study. c Transverse AWBU image of the right breast at 11:30, 6 cm from the nipple; white arrow shows a 7 mm, grade I, stage 1, invasive ductal carcinoma. d AWBU image of the left breast at 12:00, 3 cm from the nipple; two white arrows show 10 mm, grade I, stage 1, invasive carcinoma with lobular carcinoma in situ.
Retrospective review

The only detected invasive cancer over 5 cm was a non-palpable invasive lobular carcinoma, evident by AWBU but not visible even in retrospect with mammography. Another large invasive lobular cancer that occurred early in the study was not detected prospectively by either mammography or AWBU, but in retrospect is evident by AWBU.

Review of the interval cancers detected clinically within a year of negative imaging showed 9 out of 11 were evident in retrospect by AWBU, and 1 of these was also evident in retrospect by mammography. Two interval cancers were not evident on either mammography or AWBU.

Discussion

AWBU with mammography is significantly better than mammography alone for detecting breast cancer, especially for dense-breasted women. These women face a particularly difficult situation, as they may be at higher risk of developing breast cancer [41] and less likely to have the cancer detected by standard mammography screening [9–11].

The improvement in cancer detection of 3.6 per 1,000 demonstrated with AWBU is similar to supplemental yield findings of earlier studies using hand-held ultrasound (range = 2.7 to 4.6 per 1,000) [42]. However, AWBU has several advantages over handheld ultrasound. It (1) is more reproducible, thorough imaging through the entire breasts; (2) has higher definition with better contrast and sharpness and smaller images for review by using a high resolution 2,000 line reading monitor with 3D capability and (3) allows delayed interpretation at computer monitor-based read stations with non real-time review, optimizing the radiologist’s reading environment.

As 82% of interval cancers detected clinically before the next screening are apparent retrospectively on

Table 2 Non-palpable breast cancer detections by imaging methods and breast density

<table>
<thead>
<tr>
<th>Breast density according to BI-RADS</th>
<th>Number of patients</th>
<th>Number of cancers</th>
<th>Imaged only by AWBU</th>
<th>Imaged by both AWBU and mammography</th>
<th>Imaged by mammography only</th>
<th>Neither</th>
<th>p value b</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (fatty)</td>
<td>148 (2)</td>
<td>2</td>
<td>1 (50) (1.99)</td>
<td>1 (50)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>d</td>
</tr>
<tr>
<td>2 (mixed)</td>
<td>1,930 (30)</td>
<td>6</td>
<td>2 (33) (4.78)</td>
<td>2 (33)</td>
<td>1 (17)</td>
<td>1 (17)</td>
<td>1.00</td>
</tr>
<tr>
<td>3 (dense)</td>
<td>3,923 (61)</td>
<td>42</td>
<td>15 (36) (21.5,52)</td>
<td>11 (26)</td>
<td>7 (17)</td>
<td>9 (21)</td>
<td>0.13</td>
</tr>
<tr>
<td>4 (ex dense)</td>
<td>424 (6.5)</td>
<td>7</td>
<td>5 (71) (29.96)</td>
<td>1 (14)</td>
<td>0 (0)</td>
<td>1 (14)</td>
<td>0.06</td>
</tr>
<tr>
<td>3 &amp; 4</td>
<td>4,347 (68)</td>
<td>49</td>
<td>20 (41) (27.56)</td>
<td>12 (24)</td>
<td>7 (14)</td>
<td>10 (20)</td>
<td>0.02</td>
</tr>
</tbody>
</table>

Abbreviations: AWBU, automated whole breast ultrasound; ex dense, extremely dense
aInterval cancers diagnosed within 1 year of negative mammography and AWBU
b p value for comparison of number of cancers detected by AWBU versus mammography
c95% confidence intervals for additional cancers detected only by AWBU
dp value not calculated because of zero cell counts

Table 3 Patient recalls for additional studies by initial imaging method

<table>
<thead>
<tr>
<th>Imaging method</th>
<th>BI-RADS 0 n/N, %</th>
<th>BI-RADS 3 a n/N, %</th>
<th>BI-RADS 4 or 5 a n/N, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>All mammograms b</td>
<td>208/6425, 3.2%</td>
<td>39/6425, 0.6%</td>
<td>59/6425, 0.9%</td>
</tr>
<tr>
<td>Screening mammograms</td>
<td>208/4991, 4.2%</td>
<td>39/4991, 0.8%</td>
<td></td>
</tr>
<tr>
<td>AWBU</td>
<td>465/6425, 7.2%</td>
<td>77/6425, 1.2%</td>
<td>99/6425, 1.5%</td>
</tr>
<tr>
<td>Both mammography and AWBU c</td>
<td>50/6425, 0.8%</td>
<td>10/6425, 0.15%</td>
<td>24/6425, 0.4%</td>
</tr>
<tr>
<td>AWBU only d</td>
<td>415/6425, 6.45%</td>
<td>67/6425, 1.0%</td>
<td>75/6425, 1.2%</td>
</tr>
</tbody>
</table>

Abbreviations: AWBU, automated whole breast ultrasound
aClass 0 imaging studies changed to class 3, 4, or 5 after evaluation
bIncludes screening and diagnostic mammograms
cStudies where additional imaging was recommended based on both mammography and AWBU findings independently
dStudies with class 1 or 2 mammography, where additional imaging would not otherwise have been recommended
previous AWBU examinations, we postulate that cancer detection with AWBU may improve with increased reader experience and possibly a CAD system. In addition, available previous comparison studies may contribute to better sensitivity and fewer recalls. Assuming that many of the AWBU “missed” cancers could potentially be avoided, AWBU with mammography could have sensitivity approaching 95%. This may be comparable to the sensitivity of MRI, but at a fraction of the cost [14, 15, 43, 44].

The 38% PPV of biopsy for AWBU observed in this study is substantially higher than the 11% PPV of biopsy prompted by ultrasound in the ACRIN Trial [31], and higher than the 33% PPV from the Breast Cancer Surveillance Consortium (BCSC) report [45]. Perhaps our improvement in PPV occurred because the women with suspicious findings on either mammography or ultrasound screening were treated as any other recall patient in the usual manner for the particular imaging department. Consequently, the PPV found in this study is consistent with the PPV found in our institutions in general. Similarly, the recalled women who were not biopsied were assigned to a BI-RADS category of 1 (normal), 2 (benign) or 3 (probably benign). The category-3 women underwent appropriate follow-up, and the others returned to routine screening.

Additionally, only 71% of invasive cancers detected by the BCSC were smaller than 20 mm, while in this study 90% were smaller than 20 mm [45]. The smaller size of invasive cancers detected by adding AWBU to mammography suggests that this technology may have the potential to impact breast cancer survival and treatment options, though this has not yet been shown.

AWBU was well tolerated by participants and easily incorporated into breast imaging practice. Many women who are at increased risk of breast cancer do not meet the ACS criteria for annual MRI, but could benefit from more effective screening than mammography alone. The ease of use and cost at approximately $300 make AWBU an attractive alternative to MRI for women with dense breasts, family or personal history of breast cancer, or other risk factors. AWBU is well accepted by participants because of less breast compression than mammography, no exposure to ionizing radiation and no contrast medium injection.

A limitation of our study is the relatively small number of participating facilities and radiologists. Another possible limitation is that AWBU images were collected in transverse (axial) planes. However, 3D reconstruction in coronal, sagittal or any off-axis planes was possible for any discovered possible abnormality. The technique itself is limited, as are other ultrasound techniques, in women with large breasts. Patient cooperation is also necessary as motion beyond quiet breathing will degrade the examination. Plans to expand this research include more centers and a reader study. Continuing modification of the AWBU system has already produced fewer recalled participants, and a CAD system is being developed.

The number of recalls for additional imaging and/or requiring supplemental hand-held ultrasound is a drawback of this technology. This difference is partially explained by the higher cancer detection rate for AWBU compared with mammography, and partially by the availability of comparison AWBU examinations for only 31% of studies. On the other hand, nearly all mammograms had previous comparison studies. The similar PPV for biopsy recommendation based on AWBU detections compared with mammography findings indicates that AWBU does not lead to an excess of false-positive biopsies, despite the higher recall rate.

The interval cancer rate of 19.3% demonstrated in this study is also concerning. In spite of a 100% increase in cancer detections, the interval cancer rate is similar to the ACRIN trial [32], which showed only a 55% increase in detections. Most of the cancers missed at screening were high grade at the time of discovery. However, 9 of the 11 cancers initially missed with AWBU are visible retrospectively and are generally similar in appearance to the small cancers that were discovered prospectively.

As the study population in both these trials consisted of difficult-to-image, high-risk subjects, these numbers should not be compared with the general screening population.

### Table 4  Positive predictive value of biopsy recommendation by imaging method/s

<table>
<thead>
<tr>
<th>Imaging method/s</th>
<th>Number of cancers</th>
<th>Number of biopsies</th>
<th>Percentage positive</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>All positive mammograms</td>
<td>23</td>
<td>59</td>
<td>39.0%</td>
<td>26.6 to 52.6%</td>
</tr>
<tr>
<td>All positive AWBU</td>
<td>38</td>
<td>99</td>
<td>38.4%</td>
<td>28.8 to 48.7%</td>
</tr>
<tr>
<td>AWBU positive, mammogram negative</td>
<td>23</td>
<td>75</td>
<td>30.7%</td>
<td>20.5 to 42.4%</td>
</tr>
<tr>
<td>Mammography and AWBU positive</td>
<td>15</td>
<td>24</td>
<td>62.5%</td>
<td>40.6 to 81.2%</td>
</tr>
<tr>
<td>AWBU negative, mammogram positive</td>
<td>8</td>
<td>35</td>
<td>22.9%</td>
<td>10.4 to 40.1%</td>
</tr>
</tbody>
</table>

Abbreviations: AWBU, automated whole breast ultrasound; CI, confidence intervals
However, we do anticipate low sensitivity for cancer detection with mammography with this type of study population, as the imaging characteristics of cancers in the normal-risk, dense-breasted population are most likely the same as in a higher risk similar population.

**Conclusion**

Limiting AWBU examinations to a high-risk group with dense breasts, similar to the BRCA1/2 studies with MRI [40, 41], would dramatically reduce the cost per cancer diagnosis. In our study 87% of cancer detections added by AWBU were found in the 68% of studies in women with dense/very dense breasts. Further study should focus on better defining the combination of risk factors and imaging characteristics that warrant supplementation of mammography with AWBU.

**References**


**Acknowledgements** Additional contributions: We thank Wendie A. Berg, MD, PhD, American Radiology Services, Inc., Johns Hopkins Green Spring, Lutherville, Maryland, for her review of the manuscript and helpful comments. We thank the sites, participants and radiologists for their support and participation in this study. The radiologists, other than the authors, were David C. Bryan, MD, Jon M. Foran, MD, M. Linda Sutherland, MD, Jeannie Stryker, MD, Beth D. Kruse, MD, Gary Wood, MD, Catherine J. Babcock, MD, and Richard S. Steffens, MD.

Financial disclosures: This study was supported by Sonocine, Inc. Dr. Kelly is the majority shareholder of Sonocine, Inc. Dr. Dean owns shares in Sonocine, Inc. Neither author has received any form of payment from the company. Statistical analyses were conducted by independent researchers, Drs. Comulada and Lee, who have no potential conflict of interest with respect to this paper.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.


